Charles "Chuck" Charpentier

Chuck focuses on lender side commercial financing transactions for borrowers in the biotech, pharmaceutical, medical device and diagnostics, health care technologies and life science industries, as well as early, mid, and late stage technology companies.

He represents national banks, public and private financing firms, and other investment funds, advisors and managers in a variety of financing structures including syndicated loans, acquisition financings, asset-based loans and real estate supported transactions, senior secured, mezzanine, and unsecured financings. His practice involves both domestic and international transactions and multiple currency loans, including secured financings in North and South America, Asia, Australia, and Europe. Chuck has expertise in loan workouts and restructurings, bankruptcy, creditor’s rights and a variety of asset-based lending transactions including those secured by government accounts, intellectual property, equipment, and capital calls.

• Represents agents, lenders, and borrowers in syndicated, mezzanine, venture, and other loan facilities.
• Represents public and private companies in strategic joint ventures.
• Represented collateral agent and lender in a $26.45 million secured term loan facility to a pharmaceutical biotechnology company.
• Represented collateral agent and lender in a $20 million secured term loan facility to a health care biotechnology company.
• Represented collateral agent and lender in a $100 million secured term loan facility to a medical device company.
• Represented collateral agent and lender in a $20 million secured term loan and revolving line of credit facility to a biotechnology company.
• Represented collateral agent and lender in a $15 million secured term loan facility to a biopharmaceutical company.
• Represented collateral agent and lender in a $45 million secured term loan facility to a pharmaceutical company.
• Represented a collateral agent and lender on a $30 million secured term loan facility to an international therapeutics company.
• Represented lender in a $547 million secured term loan facility to a corn ethanol company in Brazil.
• Represented a lender on a $75 million secured term loan facility to a financial services company.
• Represented an agent and lender on a $80 million secured term loan and revolving line of credit facility to a cloud security technology company.
• Represented an agent and lender on a $40 million secured term loan and revolving line of credit facility to a plant microbiome technology company.
• Represented an agent and lender on a $26 million secured term loan facility to a media technology company.
• Represented an agent and lender on a $40 million secured term loan and revolving line of credit facility to an internet-based custom apparel company.
• Represented a lender on a $20 million secured term loan and revolving line of credit facility to a communications technology company.
• Represented a lender on an $11 million secured term loan facility to an education technology company.
• Represented collateral agent and lender in a $50 million secured revolving line of credit facility to a health care technology company.
• Represented public companies and underwriters in subordinated debt offerings and tender offers.
• Represented information storage company in $158 million acquisition of e-discovery services company.
• Represented government contracting company in acquisition of advanced technology company that provides secure cloud solutions.
• Represented public and private software companies in the sales and acquisitions of business divisions.

• Honors, Capital Pro Bono Honor Roll, D.C. Access to Justice Commission and the D.C. Bar Pro Bono Center (2024)
• Recognized as a “Rising Star” by Washington, D.C. Super Lawyers (2016)
• Recognized as a “Rising Star” by Massachusetts Super Lawyers, Boston Magazine (2007)